{
    "root": "314b9ef7-c6e5-44c9-9fbf-b0d35a24cd7d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sofosbuvir and Velpatasvir",
    "value": "20250306",
    "ingredients": [
        {
            "name": "VELPATASVIR",
            "code": "KCU0C7RS7Z"
        },
        {
            "name": "SOFOSBUVIR",
            "code": "WJ6CA3ZU8B"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        }
    ],
    "indications": "sofosbuvir velpatasvir indicated treatment adults pediatric patients 3 years age older chronic hepatitis c virus ( hcv ) genotype 1 , 2 , 3 , 4 , 5 , 6 infection [ ( 2.2 , 2.3 , 2.4 ) ( 14 ) ] : without cirrhosis compensated cirrhosis decompensated cirrhosis combination ribavirin .",
    "contraindications": "testing prior initiation therapy : test patients hbv infection measuring hbsag anti-hbc . ( 2.1 ) recommended treatment regimen duration patients 3 years age older genotypes 1 , 2 , 3 , 4 , 5 , 6 hcv table : ( 2.2 ) patient population regimen duration treatment-naïve treatment-experienced trials , regimens contained peginterferon alfa/ribavirin without hcv ns3/4a protease inhibitor ( boceprevir , simeprevir , telaprevir ) . , without cirrhosis compensated cirrhosis ( child-pugh ) sofosbuvir velpatasvir 12 weeks treatment-naïve treatment-experienced , decompensated cirrhosis ( child-pugh b c ) sofosbuvir velpatasvir + ribavirin 12 weeks recommended adults : one tablet ( 400 mg sofosbuvir 100 mg velpatasvir ) taken orally daily without food . ( 2.3 ) recommended pediatric patients 3 years older : recommended based weight . refer table 2 full prescribing information dosing guidelines based body weight . ( 2.4 ) pediatric patients less 6 years age , administer sofosbuvir velpatasvir ( epclusa ) oral pellets food . ( 2.4 ) instructions followed preparation sofosbuvir velpatasvir ( epclusa ) oral pellets . ( 2.5 ) hcv/hiv-1 coinfection : patients hcv/hiv-1 coinfection , follow recommendations table . ( 2.2 ) treatment-naïve treatment-experienced liver transplant recipients without cirrhosis compensated cirrhosis ( child-pugh ) , recommended regimen sofosbuvir velpatasvir daily 12 weeks . ( 2.2 ) used combination ribavirin , follow recommendations ribavirin dosing modifications . ( 2.3 , 2.4 ) patients renal impairment including end stage renal disease dialysis , follow recommendations table . ( 2.6 )",
    "warningsAndPrecautions": "sofosbuvir velpatasvir tablet contains 400 mg sofosbuvir 100 mg velpatasvir , pink , diamond-shaped , film-coated , debossed `` ase `` one side `` 9761 `` . carton contains 28 tablets ( 2 blister cards containing 14 tablets ) ( ndc 72626-2701-1 ) .",
    "adverseReactions": "sofosbuvir velpatasvir ribavirin combination regimen contraindicated patients ribavirin contraindicated . refer ribavirin prescribing information list ribavirin [ ( 2.2 , 2.3 , 2.4 ) ] .",
    "indications_original": "Sofosbuvir and velpatasvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2, 2.3, 2.4) and Clinical Studies (14)]:\n                  \n                  \n                     \n                        without cirrhosis or with compensated cirrhosis\n                     \n                     \n                        with decompensated cirrhosis for use in combination with ribavirin.",
    "contraindications_original": "Testing prior to the initiation of therapy: Test all patients for HBV infection by measuring HBsAg and anti-HBc. ( 2.1 ) See recommended treatment regimen and duration in patients 3 years of age and older with genotypes 1, 2, 3, 4, 5, or 6 HCV in table below: ( 2.2 ) Patient Population Regimen and Duration Treatment-naïve and treatment-experienced In clinical trials, regimens contained peginterferon alfa/ribavirin with or without an HCV NS3/4A protease inhibitor (boceprevir, simeprevir, or telaprevir). , without cirrhosis and with compensated cirrhosis (Child-Pugh A) Sofosbuvir and velpatasvir 12 weeks Treatment-naïve and treatment-experienced , with decompensated cirrhosis (Child-Pugh B and C) Sofosbuvir and velpatasvir + ribavirin 12 weeks Recommended dosage in adults: One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily with or without food. ( 2.3 ) Recommended dosage in pediatric patients 3 years and older: Recommended dosage is based on weight. Refer to Table 2 of the full prescribing information for specific dosing guidelines based on body weight. ( 2.4 ) For pediatric patients less than 6 years of age, administer sofosbuvir and velpatasvir (EPCLUSA) oral pellets with food. ( 2.4 ) Instructions for Use should be followed for preparation and administration of sofosbuvir and velpatasvir (EPCLUSA) oral pellets. ( 2.5 ) HCV/HIV-1 coinfection: For patients with HCV/HIV-1 coinfection, follow the dosage recommendations in the table above. ( 2.2 ) For treatment-naïve and treatment-experienced liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A), the recommended regimen is sofosbuvir and velpatasvir once daily for 12 weeks. ( 2.2 ) If used in combination with ribavirin, follow the recommendations for ribavirin dosing and dosage modifications. ( 2.3 , 2.4 ) For patients with renal impairment including end stage renal disease on dialysis, follow the dosage recommendations in the table above. ( 2.6 )",
    "warningsAndPrecautions_original": "Each sofosbuvir and velpatasvir tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir, is pink, diamond-shaped, film-coated, debossed with \"ASE\" on one side and \"9761\" on the other. Each carton contains 28 tablets (2 blister cards each containing 14 tablets) (NDC 72626-2701-1).",
    "adverseReactions_original": "Sofosbuvir and velpatasvir and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. Refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see Dosage and Administration (2.2, 2.3, 2.4)]."
}